About enveric biosciences - ENVB
Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.
ENVB At a Glance
Enveric Biosciences, Inc.
245 First Street
Cambridge, Massachusetts 02142
| Phone | N/A | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Other | Net Income | -8,771,987.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ENVB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.922 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.404 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ENVB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,461,997.833 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ENVB Liquidity
| Current Ratio | 5.328 |
| Quick Ratio | 5.328 |
| Cash Ratio | 5.093 |
ENVB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -214.514 |
| Return on Equity | -304.037 |
| Return on Total Capital | -209.98 |
| Return on Invested Capital | -304.037 |
ENVB Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |